Cortexyme Announces Pipeline Update and Anticipated 2022 Milestones

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $CRTX--Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering upstream therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today provided a business update and announced key milestones for 2022. Christopher Lowe, Cortexyme’s interim chief executive officer, chief operating officer, and chief...

Click to view original post